The field of RNA therapeutics received a boost on 10 October when a group of investors provided Series A funding to Gotham Therapeutics Inc, a company founded by Versant Ventures to develop drugs that target RNA-modifying proteins. The new company will be exploiting discoveries in the field of epitranscriptomics, a discipline which describes the biochemical modifications of RNA within a cell. These modifications help determine the degree to which genes are translated into proteins.
